The Markowitz Lab at
The Markowitz Lab at
Springer, 2021
Edited by Joseph Markowitz
Perkins RM, Markowitz J. Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center. Methods Mol Biol. 2021;2194:1-19. doi:10.1007/978-1-0716-0849-4_1
Lin TA, Eroglu Z, Carvajal R, Markowitz J. Cohort Identification for Translational Bioinformatics Studies. Methods Mol Biol. 2021;2194:35-44. doi:10.1007/978-1-0716-0849-4_3
Sun J, Kroeger JL, Markowitz J. Introduction to Multiparametric Flow Cytometry and Analysis of High-Dimensional Data. Methods Mol Biol. 2021;2194:239-253. doi:10.1007/978-1-0716-0849-4_13
Markowitz J. Preface. Methods Mol Biol. 2021;2194:v-vii. doi:10.1007/978-1-0716-0849-4
Markowitz, J., Shamblott, M., Brohl, A. S., Sarnaik, A. A., Eroglu, Z., Khushalani, N. I., Dukes, C. W., Chamizo, A., Bastawrous, M., Garcia, E. T., Delhawi, A., Chen, P. L., De Aquino, D. B., Sondak, V. K., Tarhini, A. A., Kim, Y., Lawman, P., & Pilon-Thomas, S. (2024). First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0. Molecular cancer therapeutics, 10.1158/1535-7163.MCT-23-0652. Advance online publication. doi: 10.1158/1535-7163.MCT-23-0652
Jimenez, J., Dubey, P., Carter, B., Koomen, J., & Markowitz, J. (2023). A metabolic perspective on nitric oxide function in melanoma. Biochimica et biophysica acta. Reviews on cancer, 189038. Advance online publication. doi: 10.1016/j.bbcan.2023.189038
Garg SK, Sun J, Kim Y, Whiting J, Sarnaik A, Conejo-Garcia JR, Phelps M, Weber JS, Mulé JJ, Markowitz J. Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma. Cancers (Basel). 2023 Mar 14;15(6):1755. doi: 10.3390/cancers15061755
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, Moran-Segura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, and Lau EK.. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy [published online ahead of print, 2023 Jan 23]. Nat Cancer. 2023;10.1038/s43018-022-00506-7. doi:10.1038/s43018-022-00506-7
Saha A, Dreyfuss I, Sarfraz H, Friedman M, and Markowitz J. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers (Basel). 2022;15(1):84. Published 2022 Dec 23. doi:10.3390/cancers15010084
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, and Weber J. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022;10(11):e005684. doi:10.1136/jitc-2022-005684
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, and Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022;400(10357):1008-1019. doi:10.1016/S0140-6736(22)01659-2
Yu X, Cen L, Chen YA, Markowitz J, Shaw T, Tsai K, Conejo-Garcia J, and Wang X. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Res. 2022;82(9):1724-1735. doi:10.1158/0008-5472.CAN-21-3113
Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, Eksioglu, EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022;30(6):2315-2326. doi:10.1016/j.ymthe.2022.02.005
Creed JH, Wilson CM, Soupir AC, Colin-Leitzinger CM, Kimmel GJ, Ospina OE, Chakiryan NH, Markowitz J, Peres LC, Coghill A, Fridley BL. spatialTIME and iTIME: R package and Shiny application for visualization and analysis of immunofluorescence data. Bioinformatics. 2021;37(23):4584-4586. doi:10.1093/bioinformatics/btab757
Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021;11(8):1996-2013. doi:10.1158/2159-8290.CD-20-1546
Hicks JK, Howard R, Reisman P, Adashek JI, Fields KK, Gray JE, McIver B, McKee K, O’Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021;5:PO.20.00513. Published 2021 May 20. doi:10.1200/PO.20.00513
Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother. 2020;69(12):2465-2476. doi:10.1007/s00262-020-02634-4
Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers. 2020;12(12):3515. doi:10.3390/cancers12123515
Sun J, Kirichenko DA, Chung JL, Carr MJ, Eroglu Z, Khushalani N, Markowitz J, Messina JL, Sondak VK, Zager JS, Patel SY. Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World J Surg. 2020;44(4):1283-1293. doi:10.1007/s00268-019-05314-2
Garg SK, Ott MJ, Mostofa AGM, Chen Z, Chen YA, Kroeger J, Cao B, Mailloux AW, Agrawal A, Schaible BJ, Sarnaik A, Weber JS, Berglund AE, Mule JJ, Markowitz J. Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Front Immunol. 2020;11:164. doi:10.3389/fimmu.2020.00164
Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalnai N, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020;33(1):86-95. doi:10.1111/pcmr.12813
Eroglu Z, Holmen SL, Chen Q, Khushalani N, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019;32(3):458-469. doi:10.1111/pcmr.12771
Suarez-Kelly LP, Levine KM, Olencki TE, Del Campo SEM, Streacker EA, Brooks TR, Karpa VI, Markowitz J, Bingman AK, Geyer SM, Kendra KL, Carson WE. A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. Cancer Immunol Immunother. 2019;68(4):619-629. doi:10.1007/s00262-019-02308-w
Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadam H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. Clin Cancer Res. 2018;24(22):5516-5524. doi:10.1158/1078-0432.CCR-18-0565
Johnson DB, Bordeaux JM, Kim JY, Vaupel CA, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy JW, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall JM, Markowitz J, Balko JM, Dakappagari NK. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018;24(21):5250-5260. doi:10.1158/1078-0432.CCR-18-0309
Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE 3rd. Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol. 2018;118(3):501-509. doi:10.1002/jso.25163
Perez MC, Yu HM, Markowitz J. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Rep. 2018;2018:bcr-2018-226089. doi:10.1136/bcr-2018-226089
Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018;8:44. Published 2018 Mar 2. doi:10.3389/fonc.2018.00044
Yarlagadda K, Hassani J, Markowitz J. The role of nitric oxide in melanoma. Biochim Biophys Acta Rev Cancer. 2017;1868(2):500-509. doi:10.1016/j.bbcan.2017.09.005
Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017;7(1):15424. doi:10.1038/s41598-017-14970-0
Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother. 2017;66(11):1437-1447. doi:10.1007/s00262-017-2038-3
Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250. Published 2017 Aug 29. doi:10.2147/OTT.S136992
Puri S, Markowitz J. The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. Ann Res Hosp. 2017;1:24. doi:10.21037/arh.2017.04.24
Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen AY, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016;4:85. Published 2016 Dec 20. doi:10.1186/s40425-016-0194-1
Ozgun A, Sondak VK, Markowitz J. Resistance patterns to anti-PD-1 therapy in metastatic melanoma. Chin Clin Oncol. 2016;5(6):75. doi:10.21037/cco.2016.08.01
Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther. 2016;9:5931-5941. Published 2016 Sep 29. doi:10.2147/OTT.S106288
Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE 3rd. Structural characterization of NRAS isoform 5. Protein Sci. 2016;25(5):1069-1074. doi:10.1002/pro.2916